{"entity":{"id":"btg1","kind":"target","name":"BTG1","aka":["BTG anti-proliferation factor 1","APRO2"],"tldr":"BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.","summary":"Anti-proliferative protein.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, animal model 0.47, genetic association 0.28, somatic mutation 0.79). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1130","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1130"},{"label":"UniProt P62324","url":"https://www.uniprot.org/uniprotkb/P62324/entry"},{"label":"NCBI Gene 694","url":"https://www.ncbi.nlm.nih.gov/gene/694"},{"label":"Ensembl ENSG00000133639","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133639"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","multiple-myeloma","dlbcl","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"BTG1","role":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1130","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1130","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P62324","url":"https://www.uniprot.org/uniprotkb/P62324/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene BTG1","url":"https://civicdb.org/features/638","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000133639","url":"https://platform.opentargets.org/target/ENSG00000133639/associations","note":"association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.67 (GraphQL API, CC0)"},{"label":"IntOGen BTG1","url":"https://www.intogen.org/search?gene=BTG1","note":"driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:1130","ensembl":"ENSG00000133639","uniprot":"P62324","entrez":"694","biology":"Anti-proliferative protein. Locus 12q21.33 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.67 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL)","Multiple myeloma: IntOGen driver in 1 cohort (PCM)","Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease","Chronic lymphocytic leukaemia: IntOGen driver in 1 cohort (CLLSLL)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/btg1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}